Alnylam Pharmaceuticals Inc stock is traded at $155.94, with a volume of 2,829,370. It is down -0.46% in the last 24 hours and down -30.37% over the past month. Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam's commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam's partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.
Previous Close:
$156.66
Open:
$155.22
24h Volume:
2,829,370
Relative Volume:
0.67
Market Cap:
$20.89B
Revenue:
$4.29B
Net Income/Loss:
$577.22M
P/E Ratio:
37.05
EPS:
$4.21
Net Cash Flow:
$641.34M
1W Performance:
-5.49%
1M Performance:
-30.37%
6M Performance:
-48.53%
1Y Performance:
-64.60%
1-Day Range:
$154.30$159.45
1-Week Range:
$154.30$170.49
52-Week Range:
$154.30$479.79
Alnylam Pharmaceuticals Inc Stock (ALNY) Company Profile
Name
Alnylam Pharmaceuticals IncSector
HealthcareIndustry
BiotechnologyPhone
(617) 551-8200Address
675 WEST KENDALL STREET, CAMBRIDGE, MA, USAMarket Cap
Revenue
Net Income
Cash Flow
EPS